Taking the advantage of the size and the nature of its natural existence in vivo, our results suggest that this short synthetic peptide fragment (C2ORF40MPF) of human C2ORF40 may be a potential therapeutic agent of human breast cancer and other cancers. Here, ECRG4 is linked to breast carcinoma.